BMY
Bristol-Myers Squibb Company
Set alert
- YTD
- +15.83%
- 1 year
- +36.96%
- Open
- 63.00
- Prev close
- 61.39
- Mkt cap
- 127.71B
- Vol
- 12.67M
- Avg vol
- 11.53M
- EPS
- 4.54
- P/E
- 13.76
- Div yield
- 4.10%
More statistics
- Low
- 62.29
- High
- 64.04
- Forward P/E
- 9.45
- Beta
- 0.00
- Short ratio
- 3.50
- Inst. own
- 84.93%
- Dividend
- 2.52
- Ex-div date
- Oct 1, 2026
- Earnings
- Feb 4, 2027
- 50-d avg
- 62.86
- 200-d avg
- 59.92
- 1y target
- 65.39
Key statistics
- Market cap
- 127.91B
- Enterprise value
- 0
- Trailing P/E
- 13.78
- Forward P/E
- 9.45
- PEG ratio
- 17.02
- Price / sales
- 2.56
- Price / book
- 6.90
- EPS (TTM)
- 4.54
- Beta
- 0.00
- Dividend yield
- 4.10%
- Payout ratio
- 55.29%
- Profit margin
- 18.47%
- Revenue (TTM)
- 50.03B
- Revenue growth
- 6.90%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 2.04B
- Short % of float
- 2.44%
- 50-day average
- 62.86
- 200-day average
- 59.92
Analyst view
Consensus: buy
- Target (low)
- 40.00
- Target (mean)
- 65.39
- Target (high)
- 80.00
- Strong buy4
- Buy6
- Hold16
- Sell1
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.54.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 1.57 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 1.10 | 1.35 | +0.25 | +22.73% |
| Jul 30, 2026 | Jun 30, 2026 | 1.60 | 2.04 | +0.44 | +27.50% |
| Apr 30, 2026 | Mar 31, 2026 | 1.42 | 1.58 | +0.16 | +11.27% |
| Feb 5, 2026 | Dec 31, 2025 | 1.23 | 1.26 | +0.03 | +2.44% |
| Oct 30, 2025 | Sep 30, 2025 | 1.52 | 1.63 | +0.11 | +7.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | main | Underweight | Underweight |
| Oct 26, 2026 | Piper Sandler | main | Overweight | Overweight |
| Oct 13, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 8, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 7, 2026 | Morgan Stanley | main | Underweight | Underweight |
| Oct 5, 2026 | Leerink Partners | down | Outperform | Market Perform |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- bms.com
News
- Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40
- BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Bristol Myers Squibb Q3 Earnings Call Highlights
- Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
- Bristol-Myers Squibb Says AI Is Already Speeding Up Drug Research — And It's Measuring The Impact
- BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
- Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
- Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings
- Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates
Your note
Sign in to keep a note on BMY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOERNER CHRISTOPHER S | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 9, 2026 | 146,890 |
| ELKINS DAVID VINCENT | Chief Financial Officer | Sale | Mar 31, 2026 | 159,542 |
| HALLER JULIA A | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 34,079 |
| HIRAWAT SAMIT | Officer | Purchase | Apr 24, 2025 | 83,513 |
| LENKOWSKY ADAM | Officer | Conversion of Exercise of derivative security | Apr 30, 2026 | 28,677 |
| LEUNG SANDRA | General Counsel | Conversion of Exercise of derivative security | Mar 9, 2025 | 465,374 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.83% | 180,384,994 | 11.29B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 133,337,856 | 8.34B | Jun 29, 2026 |
| State Street Corporation | 5.01% | 102,408,940 | 6.41B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.51% | 71,713,442 | 4.49B | Jun 29, 2026 |
| Charles Schwab Investment Management, Inc. | 3.31% | 67,595,177 | 4.23B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.76% | 56,443,077 | 3.53B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 64,828,989 | 4.06B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.73% | 55,842,362 | 3.49B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 52,920,170 | 3.31B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 27,218,615 | 1.70B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 26,507,921 | 1.66B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 25,286,034 | 1.58B | Sep 29, 2026 |